Apical sodium-dependent bile acid transporter, drug target for bile acid related diseases and delivery target for prodrugs: Current and future challenges
- PMID: 32201314
- DOI: 10.1016/j.pharmthera.2020.107539
Apical sodium-dependent bile acid transporter, drug target for bile acid related diseases and delivery target for prodrugs: Current and future challenges
Erratum in
-
Corrigendum to "Apical sodium-dependent bile acid transporter, drug target for bile acid related diseases and delivery target for prodrugs: Current and future challenges" [Pharmacology & Therapeutics 212 (2020) 107539].Pharmacol Ther. 2022 Jun;234:108184. doi: 10.1016/j.pharmthera.2022.108184. Epub 2022 Apr 15. Pharmacol Ther. 2022. PMID: 35437152 No abstract available.
Abstract
Apical Sodium-dependent Bile Acid Transporter (ASBT) actively reabsorbs bile acids (BAs) from the gut lumen. This process is a critical step in the enterohepatic circulation (EHC) of BAs and plays important roles in the homeostasis of BAs in the body. Therefore, ASBT is considered a favorite target for intervention to regulate the levels of BAs, cholesterol, lipid and glucose etc. In addition, ASBT is also a popular delivery target for developing prodrugs, due to its intestinal localization, high expression and high uptake capacity. In the past ten years, ASBT has been the focus by both academia and pharmaceutical industry as research targets not only for BA-related diseases but also for prodrug delivery. Numerous studies have been published and many candidate ASBT inhibitors are being developed. Here we review and summarize the current states of ASBT research with a focus on the therapeutic applications of ASBT as a target for therapy as well as a delivery target for prodrugs. The current and future challenges in ASBT research and outlook of drug developments are discussed.
Keywords: ASBT inhibitor; ASBT prodrug; Apical sodium-dependent bile acid transporter; Delivery target; Drug target; Drug-drug interaction.
Copyright © 2020. Published by Elsevier Inc.
Similar articles
-
ASBT(SLC10A2): A promising target for treatment of diseases and drug discovery.Biomed Pharmacother. 2020 Dec;132:110835. doi: 10.1016/j.biopha.2020.110835. Epub 2020 Oct 6. Biomed Pharmacother. 2020. PMID: 33035828 Review.
-
An important intestinal transporter that regulates the enterohepatic circulation of bile acids and cholesterol homeostasis: The apical sodium-dependent bile acid transporter (SLC10A2/ASBT).Clin Res Hepatol Gastroenterol. 2017 Oct;41(5):509-515. doi: 10.1016/j.clinre.2017.02.001. Epub 2017 Mar 21. Clin Res Hepatol Gastroenterol. 2017. PMID: 28336180 Review.
-
Inhibition of intestinal bile acid absorption improves cholestatic liver and bile duct injury in a mouse model of sclerosing cholangitis.J Hepatol. 2016 Mar;64(3):674-81. doi: 10.1016/j.jhep.2015.10.024. Epub 2015 Oct 31. J Hepatol. 2016. PMID: 26529078
-
Gut microbiota inhibit Asbt-dependent intestinal bile acid reabsorption via Gata4.J Hepatol. 2015 Sep;63(3):697-704. doi: 10.1016/j.jhep.2015.04.030. Epub 2015 May 27. J Hepatol. 2015. PMID: 26022694 Free PMC article.
-
Cholesterol dependent downregulation of mouse and human apical sodium dependent bile acid transporter (ASBT) gene expression: molecular mechanism and physiological consequences.Gut. 2006 Sep;55(9):1321-31. doi: 10.1136/gut.2005.085555. Epub 2006 Feb 16. Gut. 2006. PMID: 16484503 Free PMC article.
Cited by
-
Impact of Drug-Mediated Inhibition of Intestinal Transporters on Nutrient and Endogenous Substrate Disposition…an Afterthought?Pharmaceutics. 2024 Mar 24;16(4):447. doi: 10.3390/pharmaceutics16040447. Pharmaceutics. 2024. PMID: 38675109 Free PMC article. Review.
-
Collaborative Metabolism: Gut Microbes Play a Key Role in Canine and Feline Bile Acid Metabolism.Vet Sci. 2024 Feb 18;11(2):94. doi: 10.3390/vetsci11020094. Vet Sci. 2024. PMID: 38393112 Free PMC article. Review.
-
Exploiting Apical Sodium-Dependent Bile Acid Transporter (ASBT)-Mediated Endocytosis with Multi-Functional Deoxycholic Acid Grafted Alginate Amide Nanoparticles as an Oral Insulin Delivery System.Pharm Res. 2024 Feb;41(2):335-353. doi: 10.1007/s11095-023-03641-7. Epub 2023 Dec 19. Pharm Res. 2024. PMID: 38114803
-
Loss of SLC27A5 Activates Hepatic Stellate Cells and Promotes Liver Fibrosis via Unconjugated Cholic Acid.Adv Sci (Weinh). 2024 Jan;11(2):e2304408. doi: 10.1002/advs.202304408. Epub 2023 Nov 13. Adv Sci (Weinh). 2024. PMID: 37957540 Free PMC article.
-
Fecal Concentrations of Long-Chain Fatty Acids, Sterols, and Unconjugated Bile Acids in Cats with Chronic Enteropathy.Animals (Basel). 2023 Aug 30;13(17):2753. doi: 10.3390/ani13172753. Animals (Basel). 2023. PMID: 37685017 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous
